Introduction
Fabry disease (FD; OMIM: #301500) is a rare, X chromosomal inherited lysosomal storage disease due to a deficient alpha-galactosidase A enzyme (GLA) activity caused by mutations in the GLA (300644) gene. First signs and symptoms such as neuropathic and gastrointestinal pain, hypohidrosis and FD crisis appear already during childhood and early adolescence. The systemic accumulation of the sphingolipid globotriaosylceramide (Gb3) in cells and tissues leads to progressive renal failure, cardiomyopathy and recurrent cerebrovascular events limiting life expectancy in affected patients [1] . Treatment with enzyme replacement therapy (ERT) has been demonstrated beneficial in reduction of cellular Gb3 storage, leading to a disease stabilization or delay of progression [2] [3] [4] [5] . However, several studies have demonstrated that infusions with recombinant enzymes may lead to acute infusion-associated reactions (IAR) [2] , as well as deleterious long-term effects by therapy inhibition due to antibody formation [6] [7] [8] . This antibodymediated inhibition seems to be limited to male patients with FD [6] [7] [8] and especially to those with nonsense mutations [8] (probably cross-reactive immunological material (CRIM) negative) and is associated with higher plasma lyso-Gb3 concentrations [7, 8] , increased left ventricular mass [8] and a progressive loss of renal function (in terms of estimated glomerular filtration rate) over time [8] .
IARs such as shivering, pain, hypotension and eventually shock are well treatable with administration of preventive preinfusion medication (antihistamines, corticosteroids, NSAIDs) and by prolonged infusion time [2, 9] . However, knowledge about immunomodulatory effects on ERT inhibition remains scarce in FD.
Antibody formation and ERT inhibition in response to recombinant proteins have also been reported for other lysosomal diseases such as Pompe disease, and case studies demonstrated successful antibody depletion by different immune modulation therapy (IMT) protocols in affected patients [10] [11] [12] . General concepts for the prevention of antibody formation and acute intervention have recently been reviewed in detail by Doerfler and colleagues [13] .
As IMT protocols against the formation of inhibitory antibodies in patients with FD have not been developed so far, this study focuses on the effect of immunosuppression on ERT inhibition in 26 male patients with FD who underwent organ transplantations.
Methods

Patients and study design
Twenty-six male patients with classical FD were consecutively recruited at the Fabry centres of the University Hospital Muenster (n = 5), Wuerzburg (n = 10), Zurich (n = 5), Berlin (n = 3) and Mainz At the time-point of data assessment, mean age of patients was 51 AE 11 years. The mean age at FD diagnosis was 36 AE 12 years, whilst the mean age at ERT initiation was 41 AE 11 years. Thirteen (50%) patients had nonsense GLA mutations, and 14 (53.8%) had enzymatic GLA activities below 10% of wild-type GLA activity ( Table 1) . The main reasons for ERT initiation were renal insufficiency (24 of 26 patients), cardiac hypertrophy (11 of 26 patients) and FD-related acral pain (11 of 26 patients, Table 1 ). Initial ERT was either agalsidase-alfa (n = 10 [38.5%]) or agalsidase-beta (n = 16 [61.5%]) ( Table 2) . At the time-point of data assessment, three patients had been permanently switched from agalsidase-beta to agalsidase-alfa ( Table 2 ). The mean age at transplantation was 44 AE 12 years, and all transplantations were due to FD-related organ failure. One patient (patient no. 24) suffered in addition from a clear cell renal carcinoma, necessitating a nephrectomy of the right kidney before transplantation ( 21 and 22) were diagnosed with FD due to end-stage renal disease necessitating organ transplantation. In these patients, ERT was initiated immediately after transplantation and convalescence.
Biochemical analyses
The longitudinal measurement of inhibitory serum activity was retrospectively performed from frozen serum samples, which had been collected at clinical visits in participating centres. The individual time-points of the visits for every patient are shown in Figure 1 and Figure S2 . All serum samples were shipped to the University Hospital Muenster where inhibition measurements and purification of total IgGs from serum samples were performed. ERT inhibition assays were performed as reported elsewhere [7, 9] . In short, 5 lL of serum was preincubated for 15 min at room temperature (RT) with 1 ng agalsidase-alfa or agalsidase-beta. Subsequently, GLA activity was determined using 4-methylumbelliferyl-a-D-galactopyranoside (Santa Cruz Biotechnology, Heidelberg, Germany), as described elsewhere [14] . N-acetylgalactosamine (Santa Cruz Biotechnology) was used as specific inhibitor of endogenous alpha-galactosidase B activity [15] . To determine mean ERT inhibition in per cent, absolute values were compared to nonserum-treated (preincubated with 5 lL 0.7% NaCl) GLA activity of 1 ng agalsidase-alfa, or agalsidasebeta, respectively. Patients with a mean ERT inhibition >50% were designated as ERT inhibition positive according to recent literature [6, 7] . Inhibition measurements with serum samples or purified total IgG samples (description below) have been performed as triplicates. To determine total IgG content within serum samples, IgGs were isolated using the Melon Gel IgG Spin Purification Kit (Thermo Scientific, Darmstadt, Germany) according to manufacturer's instructions. In brief, 50 lL of raw serum samples were incubated with 500 lL Melon Gel to ensure sufficient protein absorption from serum samples. Subsequently, IgG contents were determined by BCA analysis (Thermo Scientific). Representative SDS-PAGE analysis ( Figure S1a ) revealed typical patterns for purified IgG samples from human serum with dominant heavy and light Fc chains.
To confirm anti-GLA antibodies in inhibition-positive samples before transplantations (n = 5 patients), Western blot analyses were performed. Immunosuppression in Fabry disease / M. Lenders et al. Total 
Results
Between 2001 and 2016, 26 classical male patients with FD from five FD centres (four in Germany and one in Switzerland) with history of renal (n = 24) or heart (n = 2) transplantation were recruited (Table 1) . Time-point of data assessment and determination of serum-mediated ERT inhibition of this retrospective cohort analysis equalled the last follow-up visit. In 13 (50%) patients, a nonsense mutation resulting in a deletion, splicing defect or abortion of the amino acid sequence was detected. The age at transplantation was comparable between patients with missense mutations and those with nonsense mutations (46 AE 15 vs 43 AE 8 years, P = 0.5331). Patients had been treated either with agalsidase-alfa (0.2 mg kg À1 bodyweight, e.o.w.; Shire Baxalta) or with agalsidase-beta (1.0 mg kg À1 bodyweight, e.o.w.; SanofiGenzyme). The mean age at data assessment was 51 AE 11 years, and time after transplantation was 80 AE 72 months. At data assessment, patients had been on ERT for 9.8 AE 3.8 years ( [7, 8] ; Table 1 ). As inhibition might be influenced by immunomodulation therapy, we retrospectively determined inhibition profiles from previous visits and assessed the dosages of prescribed immunosuppressive drugs, if available. The frequencies for the formation of inhibitory antibodies per initial compound used was 28.6% (agalsidase-alfa; two from seven patients) versus 54.5% (agalsidase-beta; six from 11 patients), demonstrating no significant difference between patients receiving either agalsidase-alfa or agalsidase-beta at ERT initiation (relative risk: 1.20 [95% CI 0.73-1.97; P = 0.6673]) prior to immunosuppression. Six patients reported IARs necessitating additional premedication with cortisone, antihistamines, pain medication (where appropriate) as well as decreased infusion rates ( Table 2) . Two of these patients (33.3%) were also tested positive for ERT inhibition.
Detailed individual profiles of all recruited patients are provided in Figure S2 . Figure 1 is representative for an ERT i+ (patient no. 11; Fig. 1a ) as well as an ERT iÀ (patient no. 14; Fig. 1b ) patient. In detail, patients have been individually treated with prednisolone (Decortin, Urbason), calcineurin inhibitors such as tacrolimus (Prograf, Advagraf) or cyclosporine A (Sandimmun), the m-TOR inhibitor everolimus (Certican) and antimetabolites such as mycophenolate-mofetil (MMF; Cellcept)/mycophenolate acid (MPA; Myfortic) and azathioprine, according to individual clinical guidelines and immunological risk profiles. ERT-na€ ıve patients who received a transplant did not develop ERT inhibition under immunosuppressive therapy after ERT initiation (0 of 8 patients), although five of these patients were under a high risk due to identified nonsense GLA mutations (i.e. CRIM negative).
In six of seven (85.7%) inhibition-positive patients, inhibition decreased directly after transplantation when high dosages of immunosuppressive medication with prednisolone (>20 mg day À1 ), tacrolimus (>5 mg day
À1
) and MMF (>1 mg day À1 ) were administered ( Table 1, Fig. 1a, Figure S2b , i, j, k, l, q). However, as seen in patients with inhibitory antibodies, tapering of immunosuppression (especially prednisolone) seemed to re-increase ERT inhibition (n = 4, median [range]: 16.6 [6.9; 36.9] %; P = 0.0972; patient nos. 2, 11, 12, 13) over time. In contrast, intensification of therapy using pulse steroid therapy with prednisolone resulted into decreased ERT inhibition values as seen in patient no. 12 ( Figure S2k ).
Serum samples from 12 patients were available prior to transplantation, whilst patients were already on ERT (Table 1) . Overall, serum-mediated inhibition decreased significantly after transplantation (pretransplantation (n = 12): 53.9 AE 24.4% ERT inhibition versus post-transplantation (≤12 months; n = 12): 41.7 AE 15.9% ERT inhibition; P = 0.0143) by 12.2 [95% CI 3.0-21.4]% (Fig. 2a) .
As suggested previously, ERT inhibition in FD seems to be IgG dependent [6, 7] . To analyse the general impact of immunomodulation on antibody titres, individual whole IgG levels prior to transplantation and during follow-up were determined. Total IgGs were isolated and measured from patients before and after transplantation (Table 1 ; n = 12; Figure S1a ). As expected, whole IgG levels decreased after transplantation (n = 12; pretransplantation: 13.5 AE 3.2 g L À1 versus post-transplantation (≤12 months): 9.6 AE 1.9 g L À1 ; P < 0.0001) by 3.9 [2.4-5.5 95% CI] ng L À1 and partially recovered (increased) with tapered maintenance therapy to 11.3 AE 3.9 g L À1 (n = 9) after 12 months (Fig. 2b) . To demonstrate that purified IgGs contain antibodies against recombinant GLA, Western blot analyses with purified patients ERT i+ samples before initialization of maintenance immunosuppressive medication (n = 5) were performed. Representative Western blots demonstrated the presence of anti-GLA antibodies recognizing agalsidase-alfa, as well as agalsidasebeta ( Figure S1b) , which is in line with recent findings demonstrating a cross-reactivity for both products [6] . Consequently, we determined specific inhibitory capacities of purified total IgG antibodies against ERT from the five ERT i+ patients before and after transplantation (Fig. 2c) . Percentage ERT inhibition per lg total IgG also decreased after initialization of maintenance therapy (0-12 months post-transplantation) significantly by 4.1 [1.6-6.5 95% CI; P = 0.0100] % ERT inhibition per lg total IgG (Fig. 2c ).
To analyse a potential impact of immunosuppression on ERT effectiveness, plasma lyso-Gb3 levels have been analysed at data assessment (n = 24) as well as retrospectively over time (n = 17 patients). Lyso-Gb3 levels at data assessment were comparable between ERT inhibition-positive and inhibitionnegative patients (ERT Figure S2 for patients (n = 17), if available. Due to the retrospective design of the study, lyso-Gb3 levels were available only from eight patients (4 ERT i+ and 4 ERT iÀ ) before and after transplantation. Interestingly, slopes for lyso-Gb3 over time were stable in both groups (P = 0.4090 and P = 0.5990, respectively).
Finally, we measured anti-GLA antibody titres preand post-transplantation within the five ERT i+ patients by ELISA (Fig. 3) . After transplantation, anti-GLA titre demonstrated a~2.2-fold decline (0.46 [0.13-0.78 95% CI; P = 0.0096]; Fig. 3) .
Discussion
In the current study, we retrospectively analysed the effect of immunosuppression on antibodymediated ERT inhibition in 26 male kidney or heart transplant recipients with FD. Our main findings are as follows: (i) ERT-na€ ıve patients under immunosuppressive maintenance therapy did not develop ERT inhibition after ERT initiation, (ii) maintenance therapy after transplantation with high dosages of immunosuppressive drugs was i+ patients (n = 5) before (pre) and after transplantations. Numbers indicate individual patients. The dotted line represents the cut-off value of 50% mean ERT inhibition. *P < 0.05, **P < 0.01, ***P < 0.001. associated with decreased ERT inhibition and decreased antibody titre in affected ERT i+ patients, (iii) tapering of IMT led to increased ERT inhibition, demonstrating a possible relationship between ERT inhibition and intensity of immunosuppression, (iv) the regeneration of IgG levels after transplantation was not associated with de novo ERT inhibition.
The overall frequency of ERT inhibition was 44.8% (8 from 18 non-immunosuppressed patients before ERT initiation), which seems to be in line with previous publications [8, 9] . The risk for the formation of inhibitory antibodies was similar in patients receiving agalsidase-alfa or agalsidasebeta at ERT initiation (at least for this small group). This has also been observed in previous studies [8] . However, to address this issue accurately, prospective studies with clearly defined infusion protocols and comparable patient groups with previously determined CRIM status need to be performed.
Comparable to other lysosomal storage disorders, an innate immune response has been described in ERT-na€ ıve FD patients. A detailed overview of the pro-inflammatory pattern in treatment-na€ ıve FD patients has been provided in detail by Mauhin and colleagues [16] . Furthermore, immunoreactions and antibody formation have been reported very early after ERT initiation in first patients with FD [2, 3] . Whilst short-term transient immunoreactions mediated by IgE and later on by IgG antibodies can be prevented by decreased dosage of applied enzymes, increased infusion time and administration of preinfusion medication such as antihistamines, corticosteroids and NSAIDs [2, 9] , the general long-term effect of especially inhibitory IgG antibodies on patients' outcome remains questionable. The difference between those IgG antibodies (inhibitory and noninhibitory) is yet not clear and will be a scope of future studies.
Studies demonstrated that most patients receiving ERT generate specific anti-GLA IgG antibodies, but the effect of high inhibitory anti-GLA IgG titres on disease progression in patients (males as well as females) is still under investigation [2, 3, 16] . However, recent studies have demonstrated that male patients suffer from a high risk for developing serum-mediated ERT inhibition, which is (i) IgG dependent [6] and (ii) associated with higher plasma lyso-Gb3 levels [7] , disease progression and more severe clinical outcome [8] . Affected male patients are mainly nonsense mutation carriers with a CRIM-negative status. Previous studies reported a significant association between the need of premedication due to IARs (probably due to IgE antibodies) and the presence of inhibitory IgG antibodies [8] . In our present study, only two patients with reported IARs were also tested positive for inhibitory antibodies. This low frequency might be due to the relative small patient group. In addition, an effect of immunosuppressive maintenance therapy on the presence of IARs and interaction between IgE and IgG antigen response might be possible. Future prospective studies need to be established to analyse the presence of IgE and IgG antibodies and their interaction in patients with FD.
Overall, immunosuppression due to transplantation led to a significant decrease of 12% inhibition within our analysed patients (n = 12). Of note, by excluding inhibition-negative patients (n = 7) from these calculations, a more prominent decrease of 24% inhibition was observed. Recent studies demonstrated increased plasma lyso-Gb3 levels in ERT inhibition-positive patients [8] , thus, decreased antibody titres due to immunosuppression might be associated with decreasing lyso-Gb3 levels. Interestingly, we detected no differences in lyso-Gb3 levels between inhibition-positive and inhibition-negative patients at data assessment, which is in contrast to previous data [7, 8] . This might point to a positive effect of immunosuppression on disease progression in ERT inhibitionpositive patients. However, because the amount of available longitudinal data in our cohort was too small to analyse, future prospective studies with specific ERT inhibition are now warranted to demonstrate a positive effect of immunosuppression on disease progression in FD patients with inhibitory antibodies. An immune response to exogenous recombinant proteins (i.e. ERT) resulting in the formation of inhibitory antibodies has also been reported for other (lysosomal storage) diseases. Due to the natural history of these diseases (i.e. more severe symptoms and manifestations and rapid disease progression), the clinical consequences of inhibitory antibodies are more severe than in FD. Hence, immunosuppressive therapies in affected patients (mostly infants) demonstrated at least a reduction of antibody titres with an amelioration of disease load for other rare diseases [10, 11, 17] . In detail, treatment periods (5 days) with 2 mg kg À1 of cyclophosphamide in combination with 0.4 mg kg À1 bodyweight of intravenous immunoglobulin (IVIG) [10] or with rituximab (375 mg m À ²) in combination with methotrexate (0.5 mg kg À1 weekly) and intravenous IVIG (500 mg mg À1 every 4 weeks) [11, 18] resulted in a decrease of antibody titres and in the latter case in the absence of inhibitory antibodies for at least 3 years [17] . Moreover, a combined treatment with bortezomib (1.3 mg m À ²), rituximab (375 mg m À ²) and MTX (15 mg m À ²) has been reported to effectively reduce antibody titres in children with Pompe disease [12] . A recent study by Elder and colleagues demonstrated that B-cell depletion and immunomodulation in CRIM-negative infants before ERT initiation successfully block the immune response to recombinant alpha-glucosidase [19] . Alternative successful approaches also included de novo synthesis or DNA replicating inhibitors such as MMF and cyclophosphamide [20, 21] . A recent review by Doerfler and colleagues summarized preclinical approaches targeting specifically B and/or T cells by different drugs [13] . To the best of our knowledge, an effect of immunosuppressive therapy on ERT inhibition has not been reported for FD, so far. Our analysis of kidney and heart transplant recipients with FD demonstrates that ERT inhibition caused by anti-GLA IgG antibodies could be suppressed by an appropriate immunosuppressive regimen.
Our analyses demonstrate that high dosages of immunosuppressive drugs such as prednisolone, tacrolimus and MMF, which are commonly used to prevent acute transplant rejection, can decrease anti-GLA IgG titre and might prevent ERT inhibition. The efficacy of immunosuppression to reduce ERT inhibition decreases when the net immunosuppression is tapered. Thus, it can be hypothesized that a certain level of immunosuppressive therapy is necessary to effectively control the development of specific and clinically relevant GLA antibodies over time. The optimal immunosuppressive regime against antibody formation in FD requires further evaluation to provide a potential therapy for FD patients with relevant ERT inhibition. However, our analysis demonstrates that none of our patients developed inhibitory antibodies when ERT was initiated after transplantation, which might indicate a protective effect of the applied immunosuppressive drugs. To prevent an immune response without immunemodulative drugs, several options might be considered. In general, a prolonged half-life of infused enzymes leading to an increased availability and therefore an increased chance for tolerization might be an option. As half-life of agalsidase-alfa and agalsidase-beta is much lower than the rotation of infusions, increased infusion frequencies (with less enzyme concentrations) [22] , or the parallel application of enzyme and chaperone therapy [23] , which increases half-life, might be an option. Interestingly, both approaches were also associated with a better outcome for treated patients [22, 23] . At least, a direct modification (glycosylation, pegylation, etc.) of infused enzymes might be an option for prolonged half-life for the second-generation ERTs.
An additional therapeutic option besides immunosuppression might be a chaperone-based therapy of FD alone, which is already available. However, this therapeutic approach is only applicable for FD patients with amenable GLA mutations [24] . Future studies are needed to analyse whether the safety profile of chaperone migalastat is better than the profiles of agalsidase-alfa or agalsidase-beta. ERT i+ patients with severe disease progression, running out of therapeutic options despite weightadapted ERT, might benefit from immune modulating therapies, as shown for Pompe disease. The most efficacious approaches to induce immune tolerance in Pompe disease medication are based on the induction of GAA-specific T regs or the reduction or depletion/suppression of B-and Tcell populations to prevent antibody production [13] . How these approaches can be transferred to FD will be the scope of future studies.
We conclude that treatment with high dosages of immunosuppressive drugs is associated with decreased antibody titres and decreased ERT inhibition in affected patients. Tapering of immunosuppression may reverse this effect. ERT inhibition-specific IMT protocols with long-term modulating properties need to be established to prevent patients from increasing anti-GLA IgG titres and to guarantee an improved disease course in ERT i+ males.
Limitations
This retrospective proof-of-concept study demonstrating an effect of immunomodulation therapy on antibody-mediated ERT inhibition in FD has some limitations. Although 26 patients with transplantations suffering from a rare disease could be recruited, the small patient number and the absence of renal biopsies might be a limitation. However, to the best of our knowledge, a larger data set of transplanted FD patients with known ERT inhibition status is not available worldwide, yet. Also, the absence of information about the presence of therapy-neutralizing antibodies in all patients due to absent samples prior to transplantation is a limitation. Due to the variation and combinations of the different immunosuppressive drugs, no clear conclusions can be drawn if the observed effects on ERT inhibition are secondary to steroids or the other drugs. To analyse this, future studies are warranted with FD patients receiving only one immunosuppressive drug. Due to the retrospective design, no flow cytometric analyses of lymphocytes and/or monocytes after transplantation could be performed, which will be a scope of future studies. As lyso-Gb3 levels were not available for all time-points and patients, no conclusions could be drawn on the longitudinal effect of immunosuppressive caused decreased ERT inhibition on lyso-Gb3 levels.
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